1-20 of 26
Mohamed H. Zaki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Clinical Trials & Observations
Meletios A. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Francesco Di Raimondo, Katja C. Weisel, Albert Oriol, Markus Hansson, Angelo Vacca, María Jesús Blanchard, Hartmut Goldschmidt, Chantal Doyen, Martin Kaiser, Mario Petrini, Pekka Anttila, Anna Maria Cafro, Reinier Raymakers, Jesus San-Miguel, Felipe de Arriba, Stefan Knop, Christoph Röllig, Enrique M. Ocio, Gareth Morgan, Neil Miller, Mathew Simcock, Teresa Peluso, Jennifer Herring, Lars Sternas, Mohamed H. Zaki, Philippe Moreau
Journal: Blood
Blood (2016) 128 (4): 497–503.
https://doi.org/10.1182/blood-2016-02-700872
Published: 2016
Journal Articles

An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Katja C. Weisel, Enrique M. Ocio, MD PhD, Francesco Di Raimondo, Markus Hansson, Mathew Simcock, Neil Miller, Ana Slaughter, Teresa Peluso, Lars Sternas, Mohamed H Zaki, Philippe Moreau
Journal: Blood
Blood (2015) 126 (23): 4225.
https://doi.org/10.1182/blood.V126.23.4225.4225
Published: 2015
Journal Articles

Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Philippe Moreau, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Katja C. Weisel, Enrique M. Ocio, MD PhD, Annamaria Cafro, Christoph Rollig, Stefan Knop, Felipe de Arriba, Mathew Simcock, Neil Miller, Ana Slaughter, Latisha Watkins, Jennifer Herring, Tsvetan Biyukov, Teresa Peluso, Mohamed H Zaki, Meletios A. Dimopoulos
Journal: Blood
Blood (2015) 126 (23): 1834.
https://doi.org/10.1182/blood.V126.23.1834.1834
Published: 2015
Journal Articles

Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment

David S Siegel, Katja C. Weisel, Meletios A. Dimopoulos, Rachid Baz, Paul G. Richardson, Michel Delforge, Kevin Song, Jesus San Miguel, MD PhD, Philippe Moreau, Xin Yu, Kevin Hong, Lars Sternas, Mohamed H Zaki, Antonio Palumbo
Journal: Blood
Blood (2015) 126 (23): 3031.
https://doi.org/10.1182/blood.V126.23.3031.3031
Published: 2015
Journal Articles

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Paul G. Richardson, MD, Craig Hofmeister, Noopur S. Raje, MD, David Siegel, MD PhD, Sagar Lonial, MD, Jacob P. Laubach, Yvonne A Efebera, MD, David H. Vesole, MD, Ajay K Nooka, Jacalyn Rosenblatt, Mohamed H Zaki, Jennifer Herring, Yan Li, PhD, Sheetal Shah, Min S Chen, Kenneth C Anderson
Journal: Blood
Blood (2015) 126 (23): 3036.
https://doi.org/10.1182/blood.V126.23.3036.3036
Published: 2015
Journal Articles

MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan

Shotaro Hagiwara, Shinichiro Okamoto, Kosei Matsue, Shinsuke Iida, Kazutaka Sunami, Takuya Komeno, Kenshi Suzuki, Kiyoshi Ando, Masafumi Taniwaki, Kensei Tobinai, MD PhD, Takaaki Chou, Hitomi Kaneko, Hiromi Iwasaki, MD PhD, Chie Uemura, Hiromi Tamakoshi, Mohamed H Zaki, Thomas Doerr, Yoshiaki Kuroda, Tatsuo Ichinohe, MDPhD
Journal: Blood
Blood (2015) 126 (23): 5374.
https://doi.org/10.1182/blood.V126.23.5374.5374
Published: 2015
Journal Articles

Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD, Antonio Palumbo, MD, Katja Weisel, MD, Enrique M. Ocio, MD PhD, Michele Cavo, MD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Hartmut Goldschmidt, MD, María Jesús Blanchard, MD, Chantal Doyen, MD, Gareth J Morgan, MD PhD, Mathew Simcock, MSc, Neil Miller, CRS, Ana Slaughter, PhD, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD PhD, Philippe Moreau, MD
Journal: Blood
Blood (2014) 124 (21): 80.
https://doi.org/10.1182/blood.V124.21.80.80
Published: 2014
Journal Articles

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Shinsuke Iida, Hiromi Iwasaki, MD PhD, Takaaki Chou, Kensei Tobonai, Kazutaka Sunami, Yoshiaki Ogawa, MD, Mari Kurihara, Shuichi Midorikawa, Mohamed H. Zaki, MD, Thomas Doerr, MSc, Kosei Matsue
Journal: Blood
Blood (2014) 124 (21): 2107.
https://doi.org/10.1182/blood.V124.21.2107.2107
Published: 2014
Journal Articles

Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

Katja Weisel, MD, Meletios A. Dimopoulos, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Antonio Palumbo, MD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Harmut Goldschmidt, MD, Concetta Conticello, MD, Angelo Vacca, MD PhD, Markus Hansson, MD PhD, Neil Miller, CRS, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD, Philippe Moreau, MD
Journal: Blood
Blood (2014) 124 (21): 4755.
https://doi.org/10.1182/blood.V124.21.4755.4755
Published: 2014
Journal Articles

Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma

Antonio Palumbo, MD, Meletios A. Dimopoulos, MD, Katja Weisel, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Hartmut Goldschmidt, MD, Maria Jesus Blanchard, MD, Concetta Conticello, MD, Angelo Vacca, MD PhD, Markus Hansson, MD PhD, Ana Slaughter, PhD, Mathew Simcock, MSc, Jennifer Herring, MD, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD PhD, Philippe Moreau
Journal: Blood
Blood (2014) 124 (21): 4770.
https://doi.org/10.1182/blood.V124.21.4770.4770
Published: 2014
Journal Articles

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment

Jeffrey Matous, MD, David S Siegel, MD PhD, Sagar Lonial, MD, R. Donald Harvey, PharmD, Claudia Kasserra, PhD, Yan Li, PhD, Min Chen, PhD, Thomas Doerr, MSc, Lars Sternas, MD, Mohamed H. Zaki, MD, Christian Jacques, MD, Jatin J. Shah, MD
Journal: Blood
Blood (2014) 124 (21): 4730.
https://doi.org/10.1182/blood.V124.21.4730.4730
Published: 2014
Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation

Steve Schey, Sujith Dhanasiri, Dawn Lee, Lars Sternas, MD, Xin Yu, Mohamed H. Zaki, MD, Jamie Elvidge, Michael O'Dwyer
Journal: Blood
Blood (2014) 124 (21): 2649.
https://doi.org/10.1182/blood.V124.21.2649.2649
Published: 2014
Journal Articles

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Clinical Trials & Observations
Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej Jakubowiak, Nizar Bahlis, Kevin Song, Andrew Belch, Noopur Raje, Chaim Shustik, Suzanne Lentzsch, Martha Lacy, Joseph Mikhael, Jeffrey Matous, David Vesole, Min Chen, Mohamed H. Zaki, Christian Jacques, Zhinuan Yu, Kenneth C. Anderson
Journal: Blood
Blood (2014) 123 (12): 1826–1832.
https://doi.org/10.1182/blood-2013-11-538835
Published: 2014
Journal Articles

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Craig C. Hofmeister, MD, David Siegel, MD, PhD, Sagar Lonial, MD, Jacob P. Laubach, MD, Yvonne A. Efebera, MD, David H. Vesole, MD, PhD, Ajay K. Nooka, MD, MPH, Jacalyn Rosenblatt, MD, MSc, Noopur Raje, MD., Mohamed H. Zaki, MD, PhD, Ye Hua, MD, MPH, Yan Li, PhD, Sheetal Shah, BA, Jianming Wang, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2013) 122 (21): 1969.
https://doi.org/10.1182/blood.V122.21.1969.1969
Published: 2013
Journal Articles

Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial

Kevin W. Song, MD, FRCPC, Meletios A. Dimopoulos, MD, Katja Weisel, MD, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Philippe Moreau, MD, Anne Banos, MD, Albert Oriol, MD, Andrew Spencer, MD, Stefan Knop, MD, Christoph Renner, MD, Nizar J Bahlis, MD, Ramesh Amatya, PhD, Xin Yu, PhD, Mara Silvia Monzini, Lars Sternas, MD, Mohamed H. Zaki, MD, PhD, Christian J. Jacques, MD, Jesús F. San Miguel, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2939.
https://doi.org/10.1182/blood.V122.21.2939.2939
Published: 2013
Journal Articles

MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age)

Katja Weisel, MD, Jesús F. San Miguel, MD, PhD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Philippe Moreau, MD, Anne Banos, MD, Albert Oriol, MD, Laurent Garderet, MD, Michele Cavo, MD, Valentina Ivanova, MD, PhD, Adrian Alegre, MD, Joaquin Martinez-Lopez, Christine I. Chen, MD, Stefan Knop, MD, Xin Yu, PhD, Latisha Watkins, Lars Sternas, MD, Christian Jacques, MD, Mohamed H. Zaki, MD, PhD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2013) 122 (21): 3198.
https://doi.org/10.1182/blood.V122.21.3198.3198
Published: 2013
Journal Articles

Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003)

David S. Siegel, MD, PhD, Paul G. Richardson, MD, Meletios A. Dimopoulos, MD, Christine I. Chen, MD, Kevin Song, MD, Ravi Vij, MBBS, MD, Nizar J. Bahlis, MD, Rachid Baz, MD, Craig C Hofmeister, MD, Katja Weisel, MD, Sundar Jagannath, MD, Sagar Lonial, M.D., Michel Delforge, MD, PhD, Moshe Talpaz, MD, Philippe Moreau, MD, Jesus F San Miguel, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Anne Banos, MD, Albert Oriol, MD, Adrian Alegre, MD, Laurent Garderet, MD, Michele Cavo, MD, Valentina L Ivanova, MD, PhD, Joaquin Martinez-Lopez, Martha Q Lacy, MD, Min Chen, PhD, Philomena Casey, Lars Sternas, MD, Mohamed H. Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2013) 122 (21): 3185.
https://doi.org/10.1182/blood.V122.21.3185.3185
Published: 2013
Journal Articles

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment

Jeffrey Matous, MD, David S. Siegel, MD, PhD, Hien K. Duong, MD, Claudia Kasserra, PhD, Min Chen, PhD, Thomas Doerr, MSc, Lars Sternas, MD, Mohamed H. Zaki, MD, PhD, Christian Jacques, MD, Jatin J. Shah, M.D.
Journal: Blood
Blood (2013) 122 (21): 5393.
https://doi.org/10.1182/blood.V122.21.5393.5393
Published: 2013
Journal Articles

Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)

Jesús F. San Miguel, MD, PhD, Katja Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Philippe Moreau, MD, Anne Banos, MD, Albert Oriol, MD, Laurent Garderet, MD, Michele Cavo, MD, Valentina Ivanova, MD, PhD, Adrian Alegre, MD, Joaquin Martinez-Lopez, Christine I. Chen, MD, Christoph Renner, MD, Nizar J. Bahlis, MD, Xin Yu, PhD, Terri Teasdale, MS, Lars Sternas, MD, Christian Jacques, MD, Mohamed H. Zaki, MD, PhD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2013) 122 (21): 686.
https://doi.org/10.1182/blood.V122.21.686.686
Published: 2013
Journal Articles

Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, MD, Katja Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Philippe Moreau, MD, Anne Banos, MD, Albert Oriol, MD, Laurent Garderet, MD, Michele Cavo, MD, Valentina Ivanova, MD, PhD, Adrian Alegre, MD, Joaquin Martinez-Lopez, Christine I. Chen, MD, Andrew Spencer, MD, Stefan Knop, MD, Nizar J. Bahlis, MD, Christoph Renner, MD, Xin Yu, PhD, Kevin Hong, MS, Lars Sternas, MD, Christian Jacques, MD, Mohamed H. Zaki, MD, PhD, Jesús F. San Miguel, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 408.
https://doi.org/10.1182/blood.V122.21.408.408
Published: 2013